HALO

Halozyme Therapeutics Inc. Healthcare - Biotechnology Investor Relations →

NO
25.0% ABOVE
↓ Approaching Was 25.7% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $50.74
14-Week RSI 51
Rel. Volume (14w) This week's trading vs. the 14-week average 1.4x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.07

Halozyme Therapeutics Inc. (HALO) closed at $63.43 as of 2026-03-20, trading 25.0% above its 200-week moving average of $50.74. The stock is currently moving closer to the line, down from 25.7% last week. The 14-week RSI sits at 51, indicating neutral momentum.

Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.07 ratio) is neutral — neither side is clearly dominating.

Over the past 1100 weeks of data, HALO has crossed below its 200-week moving average 34 times. On average, these episodes lasted 8 weeks. Historically, investors who bought HALO at the start of these episodes saw an average one-year return of +59.6%.

With a market cap of $7.5 billion, HALO is a mid-cap stock. The company generates a free cash flow yield of 2.5%. Return on equity stands at 153.6%, indicating strong profitability. The stock trades at 153.2x book value.

The company has been aggressively buying back shares, reducing its share count by 12.9% over the past three years.

Over the past 21.2 years, a hypothetical investment of $100 in HALO would have grown to $3447, compared to $795 for the S&P 500. That represents an annualized return of 18.2% vs 10.3% for the index — confirming HALO as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been growing at a 14.9% compound annual rate, with 4 consecutive years of positive cash generation.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: HALO vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After HALO Crosses Below the Line?

Across 34 historical episodes, buying HALO when it crossed below its 200-week moving average produced an average return of +57.7% after 12 months (median +47.0%), compared to +18.5% for the S&P 500 over the same periods. 91% of those episodes were profitable after one year. After 24 months, the average return was +76.4% vs +31.7% for the index.

Each line shows $100 invested at the moment HALO crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

HALO has crossed below its 200-week MA 34 times with an average 1-year return of +59.6% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Feb 2005Feb 20065240.7%+60.9%+3545.4%
Jun 2006Jun 200610.8%+307.6%+2576.4%
Jul 2006Aug 200633.9%+262.5%+2634.1%
Oct 2008Dec 20081039.2%+58.1%+1275.9%
Feb 2009Mar 2009514.0%+11.4%+1143.7%
Nov 2009Mar 20101412.9%+23.3%+1003.1%
May 2010Jun 201010.6%-6.8%+861.1%
Jun 2010Jul 201032.9%+5.4%+852.4%
Aug 2010Aug 201031.6%-5.8%+836.9%
Jan 2011Jan 201114.4%+56.6%+849.6%
Feb 2011Mar 201168.0%+71.5%+827.3%
Apr 2011Jun 2011118.4%+75.3%+886.5%
Aug 2011Oct 2011117.1%-25.0%+931.4%
Jul 2012Sep 2012735.8%+52.9%+1275.9%
Oct 2012Jan 20131533.8%+61.0%+834.2%
Jan 2013May 20131529.7%+139.8%+871.4%
May 2013Jun 2013415.8%+11.9%+798.4%
Jul 2013Aug 201338.3%+31.6%+799.7%
Apr 2014Jun 2014813.6%+108.0%+754.9%
Oct 2014Oct 201411.7%+70.9%+654.2%
Nov 2014Nov 201420.9%+80.4%+642.7%
Dec 2014Dec 201417.3%+92.9%+693.9%
Jan 2016Apr 20161331.7%+12.8%+528.0%
Apr 2016Sep 20162024.7%+32.1%+501.2%
Oct 2016Nov 2016426.9%+73.7%+530.5%
Nov 2016Jan 2017916.1%+62.3%+457.9%
May 2017May 201710.1%+48.3%+411.1%
Aug 2017Aug 201736.2%+42.8%+433.0%
Dec 2018Jan 201937.0%+30.9%+356.7%
Mar 2023Mar 202324.8%+23.5%+91.7%
Apr 2023Jul 20231112.4%+12.8%+85.1%
Oct 2023Nov 2023612.2%+58.8%+70.2%
Dec 2023Feb 2024914.3%+26.4%+70.7%
Apr 2024May 202444.3%+56.0%+64.3%
Average8+59.6%

Frequently Asked Questions

Is HALO below its 200-week moving average?

No. Halozyme Therapeutics Inc. (HALO) is currently 25.0% above its 200-week moving average of $50.74. It would need to fall to $50.74 to cross below the line.

What is HALO's 200-week moving average price?

Halozyme Therapeutics Inc.'s 200-week moving average is $50.74 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when HALO drops below its 200-week moving average?

HALO has crossed below its 200-week moving average 34 times in our data. On average, buying at that moment produced a one-year return of +59.6%. These dips have historically been decent entry points. These episodes lasted 8 weeks on average.

Is HALO a good value right now?

Here's what our data says about HALO as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 51. Free cash flow yield is 2.5%. Return on equity is 153.6%. Price-to-book is 153.2x. This is not a buy or sell recommendation — always do your own research.

How does HALO compare to the S&P 500?

Over the past 21.2 years, $100 invested in HALO would have grown to $3447, compared to $795 for the S&P 500. That's 18.2% annualized vs 10.3% for the index. HALO has outperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-03-20